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ABSTRACT 
 
Robert Lanning Sons: Regulatory Modifications of MicroRNA 
and Short Hairpin RNA Precursors 
(Under the direction of Scott Hammond) 
 
RNA-interference (RNAi) is ubiquitously used as a research tool, with dozens of 
candidates using this technology currently in FDA clinical trials. A particular segment of the 
RNAi world, short hairpin RNAs (shRNAs) seeks to enable stable, long-term reduction of a 
target protein. Here, we present an optimization of shRNA structure that allows increased 
reduction of targeted proteins as unwanted processing events are bypassed, increasing the 
amount of mature RNAi species created. In Chapter 1, we present current literature as it pertains 
to RNAi biogenesis, regulation, and optimization of shRNA effectiveness. In Chapter 2, we 
present our findings of extensive shRNA precursor degradation, and complete an unbiased 
screen for structures that bypass this degradation and optimize RNAi activity. In Chapter 3, we 
offer our observations of negative processing events associated with RNA Polymerase III 
(RNAPIII)-driven shRNAs, including but not limited to the same extensive precursor 
degradation. Together, these data present new details in the dysregulation of endogenous miRNA 
biogenesis by shRNAs, and offer guidance towards more accurate and potent engineered shRNA 
regulators less likely to induce off-target effects.  
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PREFACE 
 
 
Chapter 1, a literature review, entitled “RNAi Biogenesis and Application”, was written 
for this thesis, as was Chapter 3, a research article entitled “Defects in First Generation shRNA 
Design, and Impact on Endogenous Precursor miRNAs”. Chapter 2’s figures and text are 
incorporated from an article under review in PLOS ONE entitled “Optimizing Short Hairpin 
RNA Design to Maximize RISC Loading”. My dissertation work has also included a 
collaboration with the Hornstein lab at the Weizmann Institute of Science, which enabled 
normalization of precursor-specific deep sequencing, revealing inhibition of Dicer activity in 
amyotrophic lateral sclerosis. In addition to this authorship, which was recently accepted to The 
EMBO Journal, I am a co-author on two other collaborations with the Linnstaedt and Deshmukh 
labs that are currently in review at PAIN and Oncotarget. Together, these projects and 
publications represent my dissertation efforts. 
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Chapter 1: RNAi Biogenesis and Application 
Overview 
This chapter’s purpose is to introduce the reader to the mechanism and regulation of 
RNAi, and then show how researchers use that knowledge to study and perturb gene 
function. As an introduction, the broad strokes of RNA interference (RNAi) what it does, and 
how it does it, will be presented. The second main section, biogenesis, describes the pathway 
and its regulators, beginning with transcription of what will become a mature RNAi 
molecule, ending with what is known about how a target mRNA is repressed, and including 
descriptions of the changing RNA secondary structure throughout. Lastly, researchers’ 
harnessing of RNAi will be discussed, including the strengths and weaknesses associated 
with the main variations in input structure. Lessons regarding biogenesis preferences and 
regulation are relevant for scientists across the range of basic to clinical research.  
 
RNAi Activity 
RNA interference (RNAi) was first discovered in Caenorhabditis elegans through 
humble beginnings; ingestion or injection of double-stranded RNA (dsRNA) resulted in non-
stoichiometric knockdown of complementary messenger RNA (mRNA), pointing to the 
possibility of catalytic activity (Timmons and Fire 1998; Fire et al. 1998). Endogenous use of 
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this regulatory pathway occurs via 21-23nt single-stranded RNA called microRNAs 
(miRNAs) that are conserved and clustered across most eukaryotic species. These miRNAs 
transit a biogenesis pathway from an initial transcript, the primary miRNA (pri-miRNA) 
hundreds of nucleotides (nts) long, to precursors (pre-miRNA) ~70nts long, to the 
RNA:RNA duplex containing a mature molecule that ends up in complex with an RNAi-
induced silencing complex (RISC), through which cells can regulate protein levels (Altuvia 
2005; Bartel 2004, 2009). Within the RISC complex, the miRNA is bound by the core RISC 
protein, Argonaute (Ago). Once bound by Ago, regulation of targeted mRNAs depends on 
complementarity between the bound miRNA and the target mRNA. Though the strongest 
activity associates with the highest complementarity between guide:target, imperfect 
complementarity can still induce RNAi, such that a single miRNA could promiscuously 
regulate ~100 target sites (Zamore et al. 2000; Jackson et al. 2003; Brennecke et al. 2005; 
Farazi et al. 2008; Doench and Sharp 2004; Gu et al. 2014). 
mRNA cleavage, degradation after decapping and deadenylation, and translation 
repression are all observed consequences of RNAi induction, but there was confusion as to 
which was the main contributor to reductions in protein levels. However, the portion of the 
guide strand that most contributed to RNAi was honed in upon: complementarity between 
nucleotides 2-9, counting from the 5’ phosphate of the guide strand, and a target mRNA, was 
the minimal amount of base-pairing necessary to induce RNAi. This heptamer base-pairing 
requirement enables the promiscuity that places >30% of protein coding genes within 
regulatory control of miRNAs (Lim et al. 2005; Lewis et al. 2005; Bartel 2004; Aravin and 
Tuschl 2005; Bartel 2009; Behm-Ansmant et al. 2006; Pillai et al. 2007). 
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More recently, mRNA degradation was revealed to be the dominant mechanism of 
RNAi activity. Most protein levels resist large miRNA-mediated reductions in their quantity; 
hundreds of proteins “fine-tuned” in their expression levels are more to be expected. 
However, more than 60% of human protein-coding genes have maintained miRNA target 
sites above background levels, acknowledging the value of this fine-tuning (Baek et al. 2008; 
Selbach et al. 2008; Friedman et al. 2009; Guo et al. 2010). Cleaved mRNA is subsequently 
oligo-uridylated (1-35nt uridine 3’ tail), accompanied by 5’ decapping and 3’ degradation  
(Shen and Goodman 2004). Translational repression of mRNAs via RNAi occurs via 
mechanisms still being elucidated, but one option includes mRNA sequestration to P-bodies, 
in addition to potential decay of mRNA at that location (Liu et al. 2005; Gu and Kay 2010; 
Huntzinger and Izaurralde 2011).  
Post-transcriptional regulation doesn’t only affect mRNA, it affects mature miRNAs 
as well; their quantities can be disproportionate to pri-miRNA levels, proteins can bind pre-
miRNAs, accelerating production of the mature strand, and ubiquitously expressed pri-
miRNA transcripts can be blocked from producing their mature miRNAs except in a tissue-
specific fraction of backgrounds (Eis et al. 2005; Trabucchi et al. 2009; Obernosterer 2006; 
Thomson 2006). Even increased cell-cell contact can affects microRNA biogenesis by 
enhancing Drosha activity, as well as overall RNAi activity through more efficient formation 
of RISC (Hwang et al. 2009). 
A major driving force within the field of miRNAs has been the discovery of their 
dysregulation in multiple diseases, most prominently cancer. Impaired biogenesis enhances 
cell transformation and tumorigenesis, and on the diagnostic/prognostic side, miRNA 
quantitation can discriminate between more and less aggressive subtypes of cancer. Multiple 
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factors result in miRNA dysregulation, including reductions in levels of biogenesis 
machinery proteins. Overall, global miRNA expression is lower in cancer vs. normal tissues, 
such that globally higher levels of miRNA expression equate to a more differentiated cell 
state (He et al. 2005; Lu et al. 2005; Blenkiron et al. 2007; Kumar et al. 2007; Chang et al. 
2008). 
The use of the RNAi pathway has been incredibly influential within the scientific 
community, with over 70,000 papers referencing siRNA or shRNA in a rudimentary search 
of PubMed, dozens of clinical trials currently in Phase I/II, and a first for the field, 
completion of Phase III for an RNAi therapeutic expected in 2016 (Haussecker 2015; 
Kubowicz et al. 2013; Haussecker and Kay 2015; PRNewswire 2015). However, the dangers 
of dysregulated biogenesis of miRNAs as summarized previously are stark reminders of the 
delicacy that must be employed if the RNAi pathway is to be effectively deployed on 
researchers’ and clinicians’ behalves. Below, the components of biogenesis will be presented, 
prior to concluding this chapter with a discussion of artificial RNAi tools and their intended 
and unintended interactions with biogenesis machinery. 
Biogenesis 
The immediately subsequent sections will describe the journey of an endogenous pri-
miRNA transcript through the microprocessor complex, consisting of Drosha and DGCR8, as 
its’ 5’ and 3’ single-stranded RNA flanks are cleaved to leave behind a ~70nt pre-miRNA, 
the canonical stem-loop hairpin. The precursor is then transported to the cytoplasm by 
Exportin-5 (XPO-5), for subsequent cleavage of the loop by Dicer, resulting in a ~21nt 
double-stranded RNA (dsRNA) duplex, one of which is the mature miRNA, or guide strand, 
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the other which is a passenger strand, intended to be degraded instead of incorporated into 
RISC (Fig. 1.1). This primer on biogenesis will conclude after a discussion of post-
transcriptional modifications and their effects on biogenesis regulation, followed by a 
presentation of how researchers have harnessed RNAi. 
 
 
Figure 1.1: Canonical miRNA Biogenesis. Drosha and DGCR8 measure the secondary 
structure, cleaving the 5’/3’ flanks to produce a pre-miRNA with thermodynamically 
unstable stem ~19 nucleotides in length. The pre-miRNA transits the nuclear pore complex 
via Exportin-5, after which Dicer cleaves the loop, producing a dsRNA guide-passenger 
duplex. The guide strand is bound by Ago, allowing RNAi activity.  
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Microprocessor Complex: Drosha/DGCR8 production of pre-miRNA 
Pri-miRNA transcripts originate in the nucleus, and can vary in length, interaction 
with splicing machinery, polyadenylation, and be independent transcripts or lie within other 
mRNAs. The presence of a precursor structure within the 3’ UTR of another mRNA or an 
intronic region only moderately inhibits the protein production from that parental mRNA 
(Bracht 2004; Cai 2004; Kim and Kim 2007; Morlando et al. 2008; Melamed et al. 2013). 
Drosha and DGCR8 form the Microprocessor complex that cleaves the 5’ and 3’ flanking 
sequences of the pri-miRNA to produce a pre-miRNA hairpin ~70nt in length with a 5’ 
phosphate and a 2nt 3’-OH overhang. (Denli et al. 2004; Landthaler et al. 2004; Gregory et 
al. 2004; Han 2004; Nguyen et al. 2015; Basyuk et al. 2003; Lee et al. 2003). Two DGCR8 
proteins measure 22 basepairs from the hairpin loop; ~97% accurate and precise Drosha 
cleavage occurs if the 5’ and 3’ ssRNA flanks are 11nt away from where these DGCR8 
protein measure (Han et al. 2006; Ma et al. 2013). Both secondary structure and primary 
sequence can work in concert with multiple proteins, including hnRNP A1, SMAD, p53, and 
Drosha, to enhance cleavage and production of pre-miRNA (Guil and Cáceres 2007; 
Michlewski et al. 2008; Davis et al. 2008, 2010; Suzuki et al. 2009; Auyeung et al. 2013). Of 
particular interest once harnessing of RNAi, and how miRNA-like features enhance our 
ability to induce RNAi, will be discussed, pri-miRNAs that are not cleaved by Drosha 
concurrent with their transcription are less efficiently processed to mature miRNA form 
(Pawlicki and Steitz 2008). 
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Exportin-5: the regulator of nuclear pre-miRNA export 
Exportin-5 (XPO-5) is a karyopherin that includes among its cargo pre-miRNA, for 
export through the nuclear pore complex into the cytoplasm, in a Ran-GTP dependent, 
saturable manner. XPO-5 prefers >16nt of dsRNA in the stem, and the 5’ phosphate and 3’-
OH overhang that result from Drosha processing. However, it can accommodate a 3’ blunt 
end, has no loop preference, but a 5’ overhang is inhibitory (Yi 2003; Bohnsack et al. 2004; 
Lund 2004). In addition to transport, XPO-5 may act as a reservoir for pre-miRNA, 
protecting them from nuclease cleavage (Zeng and Cullen 2004). In addition to competition 
amongst precursors, another cargo for XPO-5 is Dicer mRNA; overexpression of pre-
miRNAs results in reduced Dicer levels (Bennasser et al. 2011). Inactivating mutations in 
cancer traps precursors in the nucleus, reducing biogenesis and RNAi activity; additional 
expression of XPO-5 reverses precursor segregation, biogenesis and activity, and produces 
tumor-suppressing effects (Sonia A Melo 2010). 
 
Dicer 
Prior to becoming a single stranded guide miRNA, the loop and passenger strand 
must be removed. The canonical pathway consists of cytoplasmic Dicer that cleaves the 
dsRNA from the loop using two RNAseIII domains, producing a dsRNA that now has two 
3’OH overhangs. The Paz domain, also present in Ago2, binds both free ends of the 
precursor. (Hutvágner et al. 2001; Knight 2001; Song et al. 2003; Lingel et al. 2004; Zhang et 
al. 2004; Gurtan et al. 2012). A dsRNA binding domain contains a non-canonical nuclear 
localization signal, and though Dicer has been reported in the nucleus, evidence of its 
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contribution to miRNA biogenesis and RISC maturation have been limited to the cytoplasm 
(Doyle et al. 2013; White et al. 2014; Gagnon et al. 2014). Lastly, Dicer’s helicase domain 
assists in transitioning thermodynamically unstable substrates to RISC (Soifer et al. 2008). 
Two double-strand RNA-binding proteins (dsRBPs), TRBP and PACT, interact with Dicer 
and are required for precursor maturation into RISC. They balance each other; TRBP inhibits 
protein kinase R (PKR) and its downstream innate immune response, while PACT activates 
PKR (Chendrimada et al. 2005; Kok et al. 2007). 
Once the precursor is cleaved, the RNA duplexes unwind, with the mature 
miRNA/guide strand entering into complex with Ago2, and the passenger strand being 
destroyed. This loading happens in an asymmetric manner based upon thermodynamics: the 
5’ end with weaker binding relative to the opposite strand of the RNA duplex is the strand 
destined to become the guide. Dicer makes this comparison of the ~4 basepairs of each end; 
the RNA duplexes shift within for sensing of thermodynamic asymmetry (Schwarz et al. 
2003; Chendrimada et al. 2005; Kok et al. 2007; Noland et al. 2011). 
In addition to sensing thermodynamic stability, Dicer recognizes changes in miRNA 
precursor structure, altering its efficiency and positioning of cleavage. Both the 5’ and 3’ 
ends of precursor miRNAs are recognized by Dicer; +/-1nt differences in length of the 3’ 
overhang are slightly tolerated; +/-2nt changes in the overhang length are sub-optimally 
processed. Additionally, Dicer prefers a precursor with a base-paired 5’ end and a large loop, 
but outside of these restrictions, is flexible in terms of potential substrates (Park et al. 2011; 
Feng et al. 2012). Within the stem, Dicer ignores asymmetric bulges; i.e. a single nt extra 
bulge on the 3p strand results in a 3p mature miRNA 1nt longer than if the bulge were 
9 
symmetric, contributing to the length and positioning diversity observed with some 
endogenous microRNA guide strands (Starega-Roslan et al. 2011). 
 
RNAi-induced Silencing Complex (RISC) 
After thermodynamic sensing and comparison of the base-pairing strength of 5’ ends 
of the guide:passenger duplex by Dicer, the guide is chosen and incorporated into the 
catalytic engine of RNAi, RISC. RISC was discovered in Drosophila to contain an RNA-
directed nuclease and a guide RNA, later identified as Argonaute 2 (Hammond et al. 2000, 
2001). This guide strand can then direct RISC for cleavage of a series of complementing 
mRNA targets (Hutvágner and Zamore 2002; Martinez et al. 2002). The PIWI domain, 
similar to ribonuclease H, confers “slicing” ability on Argonaute 2 opposite the guide strand, 
and the PAZ and PIWI domains together form a groove for guide/target mRNA substrate 
binding. In mammalian cells, only Ago2, out of Ago 1-4, has this cleavage ability, and 
miRNAs indiscriminately associate with all four Agos (Lee et al. 2004)(Lee et al. 2004)(Liu 
2004; Meister et al. 2004; Song et al. 2004). In addition to cleaving passenger strands and 
target mRNAs, Ago2 can also cleave the 3P of a few pre-miRNAs in the same position, 
forming a hairpin with a 3P ~11-12nt shorter, termed Ago2-cleaved precursor miRNA (ac-
pre-miRNA) (Diederichs and Haber 2007). Surprisingly, there are a few reports of pre-
miRNA guiding active RISC via Ago2 in the absence of Dicer (Tan et al. 2011, 2009). It is 
interesting to speculate whether an ac-pre-miRNA is the actual guiding component, not an 
uncleaved pre-miRNA, especially within the context of our observations described in 
Chapters 2 and 3. 
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In humans, miRNA precursors, together with Ago2, Dicer, and TRBP, are sufficient 
to assemble, in an ATP-independent manner, RISC capable of cleaving complementary RNA 
targets. Importantly, Ago2 and Dicer can be in complex, termed the miRNA loading complex 
(miRNP), prior to pre-miRNA substrate presence, likely coupling Dicer processing of 
precursor to unwinding and Ago2 loading. Once bound, the miRNP complex cannot be 
exchanged, and expression of mRNA complementary to an Ago-bound guide strand is 
positive feedback that increases the quantity of that Ago-bound guide strand, likely through 
increased stability (Krol et al. 2010; Maniataki 2005; Flores et al. 2014). This preservative 
observation makes sense, as increasing Ago levels increases mature miRNA levels, 
extending their half-lives, acting as a reservoir (Winter and Diederichs 2011). Though 
miRNA:mRNA duplexes have been found to exist in cells without Ago association, and there 
are 13-fold more miRNA than Ago proteins in a cell, Ago-bound miRNA is a better indicator 
of a miRNA’s potency than overall expression (Janas et al. 2012; Flores et al. 2014). 
In Drosophila, dsRNA with perfect stems, termed siRNAs, segregate into different 
Argonaute proteins. A bulge in the Ago2 cleavage site (opposite nts 9/10 from the 5’ 
phosphate), shunts dsRNA to RISC incorporation around Ago1. This bulge/no-bulge 
determinant trumps the 5’ thermostability asymmetry rule of sorting controlled by Dicer. 
Similar mismatches between a guide strand and a target mRNA similarly inhibit Ago2 
cleavage of the target mRNA. Mismatches 5’ or 3’ of this central stem region, nucleotides 9-
11, as well as G:U non-canonical basepairs also shunt a dsRNA away from Ago2. These less 
thermodynamically stable structures are the majority of precursor structures in mammalian 
miRNAs: ~80% of endogenous mouse guide:passenger duplexes contain central/seed, 
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central/seed/3’, or seed/3’ mismatches (Okamura et al. 2004, 2009; Czech et al. 2009; 
Kawamata et al. 2009; Förstemann et al. 2007). 
This Ago preference in Drosophila dovetails well with what knowledge surrounding 
mammalian Agos; they overlap more in terms of guide strand binding, regardless of RNA 
duplex thermodynamic stability/stem-central bulges. Ago1 and Ago2 can both utilize 
perfectly matched stemmed siRNAs (even though only Ago2 can cleave and unwind them), 
and all Agos can utilize bulged miRNA duplexes for translational repression. Magnitude of 
potential repressive ability, regardless of the initial bulged or non-bulged stem nature of the 
input RNA:RNA duplex, remains equivalent across the four Agos (Su et al. 2009).  
 
Post-Transcriptional Modifications and their Regulatory Impact on miRNAs 
The post-transcriptional modifications and regulation most studied surround the 
conserved let-7 family. Lin28 binds a “GGAG” motif in the loop of pre-let-7, recruiting the 
terminal-uridyl transferases (TUTase) TUT-2,4,7 to the precursor for subsequent oligo-uridyl 
tailing (~15 nt in length). The length of the oligo-uridine tail determines what occurs next; a 
mono-uridyl tail results in the optimal 2-nt overhang for subsequent Dicer processing of let-7 
precursors, while a longer tail becomes a substrate for DIS3L2 3’-5’ exonuclease activity and 
inhibition of Dicer processing. This regulatory mechanism can result in a ubiquitously 
expressed precursor, for which its cognate mature strand is absent (Heo et al. 2008; Newman 
et al. 2008; Hagan et al. 2009; Heo et al. 2009; Thornton et al. 2012; Ustianenko et al. 2013; 
Heo et al. 2012). 
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Precursor miRNAs are commonly modified (5-15% of their species’ deep-sequencing 
reads), typically via 3’ monoadenylation or mono-/oligo-uridylation. Uridine tails average 5-
7nt in length, and are usually associated with trimming events or concentrated more heavily 
with precursors containing a Lin28 binding motif. Overall, positioning and modification of 
the 5’ is stable, while the 3’ terminus is relatively unstable (Burroughs et al. 2011; Newman 
et al. 2011). Uridyltransferases TUT-4/7 are localized to the cytoplasm, while components of 
the exosome, RRP6 and DIS3, are localized to both the cytoplasm and nucleus. Ago-bound 
precursors have been found to be surveilled for appropriate 3’-OH overhang length by RRP6 
and DIS3: RRP6 prefers <1nt overhangs, while DIS3 prefers >2nt overhangs. Together, 
TUT-4/7 are used to signal precursors for DIS3 degradation, fine-tuning mature expression 
levels (Liu et al. 2014) 
Tailing, such as 3’ adenylation and uridylation, is a mechanism or language of 
control. In Chlamydomonas, uridylation of mature miRNAs can induce instability and inhibit 
Dicer processing(Ibrahim et al. 2010). In Arabidopsis, the addition of 1-5 uridines to the 3’ of 
guide strands results in degradation, particularly when a target RNA with extensive 
complementarity is present (Li et al. 2005; Yang et al. 2006; Ameres et al. 2010). This 
language of control extends to target mRNAs as well; miRNAs induce oligouridylation of 
complementary sequences (Lim et al. 2014). 
In mammals, uridylation of guide strands can modify a target profile, releasing a 
target from repression, and do not predict Ago-association, removal, or degradation (Jones et 
al. 2009; Flores et al. 2014). Monoadenylation by the non-canonical poly(A) polymerase 
PAP-associated domain containing 4 (PAPD4) can reduce RISC targeting or stabilize 
selective species of mature miRNAs (Burroughs et al. 2010; Ambrogio et al. 2012; Katoh et 
13 
al. 2009). However, adenylation by PAPD5 can recruit the poly(A)-specific ribonuclease 
(PARN), resulting in mature miRNA degradation (Boele et al. 2014). This compilation of 
non-templated additions associated with changes in stability may not be the whole story 
though; some miRNA species are more stable than others without any observed changes in 
terms of non-templated modifications (Gantier et al. 2011). 
 
Biogenesis pathway: enhancing vs. inhibiting RNAi usage 
 The previous sections describe the major known factors involved in miRNA 
biogenesis. We understand the main ways in which miRNAs exert influence on 
complementary mRNAs. The second half of this review will cover the successes and failures 
as we have attempted to harness RNAi. As you might imagine from the ease with which 
dysregulation of the biogenesis pathway results in transformation and tumorigenesis, many 
portions of the biogenesis pathway have been shown to be negatively affected by our 
attempts to artificially direct RNAi activity. The promiscuity of targeting is also an issue; 
when a single nucleotide change in the length/position of a guide strand can release a target 
from repression, or introduce a new, unintended target, understanding and optimization of 
biogenesis is required for trust of these tools. 
We have read about oligouridylation being a language of clearance. A couple of 
sections below, we will discuss a common first generation tool with which the scientific 
community commonly harnesses RNAi, a tool currently in human clinical trials: a precursor 
with a 5-uridine tail, transcribed at a high level of expression. Chapter 3 will present some 
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negative effects we have observed, both with regard to the tool, as well as to endogenous 
precursors.  
The more we learn about biogenesis, the more we understand why some attempts to 
harness RNAi did not show promise; asymmetric bulges that were previously tested were not 
known at the time to shift Dicer cleavage, introducing unwanted flanking nucleotides into 
guide strands, potentially releasing targets from optimum levels of repression. The sensitivity 
of the Drosha/DGCR8 ruler similarly would introduce cleavage products beneath the 97% 
accurate and precise product that now understood, can be obtained. 
 We have identified many contributors to successful RISC formation. Some RNAi 
harnessing seeks to skip steps of biogenesis. However, we also see transcription that when 
unlinked from (Drosha) processing, reduces subsequent processing efficiency. What 
reductions in processing efficiency are bottlenecks leading to endogenous miRNA 
dysregulation and toxicity? The field has moved towards how to apply RNAi to a gene of 
choice, with minimal disruption to the biogenesis pathway’s other responsibilities. The 
remainder of Chapter 1 will present the best piggy-back methods currently known, and 
Chapters 2 and 3 will present some previously unknown factors that negatively affect tools 
currently in use both at the bench and in the clinic. 
 
Harnessing RNAi 
Research at the bench and the clinic has focused on the most effective and least toxic 
avenue for deployment of RNAi-based tools (Rao et al. 2009). Current options include short-
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interfering RNAs (siRNAs), short-hairpin RNAs (shRNAs), miRNA-like shRNAs 
(shRNAmirs), and non-canonically processed shRNAs called AgoshRNAs. siRNAs are 
perfect RNA duplexes that skip directly to RISC incorporation, and are time- and cell-limited 
in their use due to their dependence on transfection. Plasmid and lentiviral production of the 
other forms of shRNA allows a large extension of potential targets, as well as the use of the 
wide range of regulatable RNAPII promoters. shRNAs are perfectly-stemmed shRNAs, 
usually transcribed by RNA polymerase III (RNAPIII) to produce solely the pre-shRNA, 
intended to skip Drosha processing. shRNAmirs, however, maintain a loop, and 5’/3’ flanks 
from endogenous miRNAs, transiting the entirety of the canonical miRNA biogenesis 
pathway. Some maintain bulges in their stems, but this structural modification does not 
describe the majority in use. AgoshRNAs have shorter stems than normal, a smaller loop, 
and transit a Drosha- and Dicer-independent pathway on their way to RISC formation 
described at the conclusion of this chapter. 
Expanding beyond single-target knockdown, a common use of RNAi is in genome-
wide screens using shRNA libraries, the goal being 70% knockdown of each target mRNA 
from each shRNA. Approximately 30% of shRNAs using a H1-promoter/RNAPIII perfectly-
stemmed library attain the 70% level of knockdown (Bernards et al. 2006). In addition to the 
need for increases in efficacy, off-target effects due to heterogeneous processing are an area 
that needs optimization, otherwise producing false positives. Strong candidate genes, 
identified via siRNA to impact the pathway of a researcher’s interest are not consistently 
replicated in pooled shRNA library screens, and the reverse is also true. Genes reported to be 
relevant to a pathway of interest via siRNA, but that cannot be replicated via shRNA, could 
merely be due to inefficient processing of the shRNA. However, genes reported to be 
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relevant via shRNA, but that cannot be replicated by siRNA, indicates inaccurate shRNA 
processing, and subsequent off-target effects may be the culprit. A strong indicator of this 
off-targeting is the low level of overlap between siRNA and shRNA screens; 80-95% of 
candidate genes identified by the pooled shRNA screen were not shared by the siRNA screen 
(Bhinder and Djaballah 2013; Bhinder et al. 2014a). One possible contribution to off-
targeting, observed for a pLKO first generation shRNA: siRNAs replicating alternate 
processing sequences from the hairpin other than merely the guide strand reproduced the off-
target knockdowns produced by the hairpin precursor (Bhinder et al. 2014b). 
Beyond laboratory use, one of the most appealing uses for RNAi is antiviral gene 
therapy, particularly because RNAi is already the cell’s innate immune response against 
viruses, and the promiscuous activity viewed as a negative elsewhere makes it more difficult 
for error-prone replication to allow antiviral escape. Research includes HIV-1 therapies, with 
an HCV therapy driven by an attenuated RNA polymerase III (RNAPIII) U6 promoter 
currently in clinical trials (Brake et al. 2006; Berkhout and Liu 2014; Borel et al. 2014; 
Lavender et al. 2012; Haussecker and Kay 2015). Deep-sequencing of the shRNA small 
RNA products from the HCV therapeutic was published in early 2014, showing a high level 
of heterogeneity: a range of 3-4 nucleotides for 5’ and 3’ strand positioning, inclusion of loop 
nucleotides that should have been removed by Dicer, and poor strand bias (i.e. both 
passenger and guide strands were produced). This high level of heterogeneity mimics that of 
the unintended guide strands, the siRNAs that replicated pLKO off-target effects (Bhinder et 
al. 2014b). 
In the subsequent sections, we will discuss the toxicities and sources of toxicities 
associated with some previous attempts to harness RNAi. We will be comparing shRNAs to 
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shRNAmirs, and conclude with a discussion of AgoshRNAs due to our observations in 
Chapters 2 and 3 of intermediates that overlap with the mechanism of AgoshRNA 
biogenesis. shRNAs are generally stronger than shRNAmirs in terms of efficacy, but the 
latter have closed much of the gap, while the toxicity, inefficient processing, and off-target 
effects of the former remain (Boudreau et al. 2008a). Regardless, shRNAs have taught us a 
lot about which portions of the biogenesis pathway can be toxically saturated, what can go 
wrong with exogenous use of endogenous RNAi machinery. Though shRNAmirs are much 
less toxic, through reduced levels of transcription and more endogenous-like structures, they 
require more effort on the part of researchers to achieve the same levels of efficacy. 
 
shRNAs and lessons from siRNAs 
RNAi was discovered as dsRNA, sliced up to produce siRNA. A key step in 
harnessing RNAi to silence genes was in producing siRNA from DNA, the main method 
being linking a 5P strand to a 3P strand via a <10 nucleotide loop, producing short hairpin 
RNA (shRNA) precursors, usually transcribed by RNAPIII. An early shRNA precursor had 
19bp of uninterrupted RNA duplex stem, a 4 nt loop, and a 3’ oligouridine termination 
sequence 4-5 nts in length, and was designed to skip Drosha processing. Of particular note, 
shRNAs were less effective than siRNAs at lower concentrations, an initial observation that 
processing bottlenecks may exist (McManus et al. 2002; Brummelkamp et al. 2002; Paddison 
et al. 2002). The RNAPIII-transcribed pLKO.1 shRNA library, maintained by The RNAi 
Consortium, otherwise known as the Mission library, and the source for vectors used in 
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Chapter 3, is similar in structure to that previous described, consisting of a 21-mer stem, a 
6nt loop, and the same 4-5 nt oligouridine terminus (Moffat et al. 2006). 
The main goal of shRNA usage is to produce a guide strand that is incorporated into 
Ago-RISC. We learned a lot about this mechanism of incorporation and maturation of RISC, 
specific to Ago2, from siRNAs. While miRNAs are unwound, the passenger strand of an 
siRNA duplex is perfectly basepaired, and so can be cleaved, opposite nucleotides 9/10 from 
the 5’ phosphate of the guide strand, accelerating the removal of the passenger strand. 
Cleavage-resistant bulged substrates, however, are rate-limiting because they must be 
unwound down a different, slower pathway (Matranga et al. 2005; Miyoshi et al. 2005; Rand 
et al. 2005; Rivas et al. 2005; Kim et al. 2007). This Ago2-specific cleavage phenomenon is 
further exacerbated in Ago1/3/4: increasing siRNA thermodynamic stability blocks 
passenger strand unwinding, while remaining sensitive to Ago2 cleavage (Petri et al. 2011). 
Now, let us discuss some of the many ways shRNA expression can perturb something 
other than that which is intended. Exportin-5 was found to be a saturable portion of the 
miRNA/shRNA biogenesis pathway in the presence of high doses of AAV-introduced 
RNAPIII-transcribed shRNAs. This shRNA saturation of XPO-5 harkens back to Zeng and 
Cullen’s 2004 interpretations of Exportin-5 as a protective reservoir for endogenous 
precursors, which when absent (or in the case of RNAPIII-transcribed shRNAs, already at 
capacity) might indicate global reductions in mature miRNA quantity. Subsequently, Ago2 
was also found to be saturable; overexpression of both Ago2 and XPO-5 increased 
knockdown capability and stability and relieved toxicity. The secondary structure of RNA 
components also affected toxicity: high levels of guide:passenger complementarity, as well 
as guide:target complementarity, were toxic. This structure/toxicity relationship may be 
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connected to the Ago2 vs. Ago1/3/4 difference in terms of slicing ability (Ago2), perhaps the 
inability of Ago1/3/4 to unwind highly thermodynamic base-pairing (siRNAs and shRNAs) 
as sources of toxicity (Grimm et al. 2006, 2010).  
Examples of shRNA-mediated toxicity abound: shRNA expression from an RNAPIII 
U6 promoter was found to contribute to MYC-induced carcinoma, globally disrupting 
miRNA expression (Beer et al. 2009). Hepatitis B virus treatment with adeno-associated 
virus gene therapy carrying U6-driven shRNAs was toxic, and reductions in transcription 
levels via the weaker RNAPII H1 promoter reduced toxicity, but with concurrent reductions 
in shRNA potency (Sun et al. 2013). In utero electroporation of shRNA, but not miRNA or 
siRNA produced off-target effects, disrupted endogenous miRNA levels, and suppressed let-
7 production via saturated Dicer, which was alleviated via transfer of the guide/passenger 
strands to an endogenous miRNA loop + flank backbone (Baek et al. 2014). Yet another U6-
driven report of toxicity was due to increased accumulation of the shRNA guide strand over 
3 weeks (Ahn et al. 2011).  
We have seen that reduced levels of transcription could avoid toxicity, but potency 
from the traditional shRNA structure in addition to lower levels of transcription is difficult: 1 
of 380 tested worked in one study, when attempting to transition from a U6 to weaker H1 
RNAPIII promoter. shRNA design parameters are not aligned for potency in conjunction 
with use at lower levels of expression (Shimizu et al. 2009). In a different report, the 
transition from U6 to H1 resulted in similar target knockdown, indicating a saturable 
bottleneck after which additional knockdown cannot be attained, regardless of transcription 
levels of this type of shRNA (Brake et al. 2008). Additionally, the RNAPIII promoters 
typically used for shRNA transcription are promiscuous in their position of initial nucleotide, 
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a range of 3-4 nucleotides for the U6 and H1 promoters, and an even larger range of initial 
nucleotide position was observed for the modified/attenuated U6 promoter currently in anti-
HCV clinical trials (Ma et al. 2014a; Denise et al. 2014). 
RNAPIII-transcribed shRNAs are effective, but likely due to brute-force transcription 
of precursors, not through efficient processing. A researcher still has to test 3-4 to get a good 
knockdown, with off-target effects that may not be immediately obvious. We have learned 
that much of the endogenous biogenesis machinery can be saturated, displacing, 
dysregulating, and globally repressing endogenous miRNA levels. All in all, traditional 
shRNA design and usage parameters just do not seem to be aligned regarding high levels of 
target repression, in conjunction with use at lower levels of shRNA expression. Next, we will 
discuss the more efficient shRNAmirs, which have been optimized to compete with the high 
level of knockdown initially produced from artificial, RNAPIII-transcribed shRNAs, but 
without toxicity. 
 
shRNAmirs: miRNA-like structures enhance tolerance and biogenesis  
We will begin this section by discussing the main shRNAmir libraries commercially 
available, then discuss the components of shRNAmir structure and processing that ablate the 
toxicity and match the efficacy observed for shRNAs, and conclude this section with some 
examples of miRNA-like stem structures that have previously been used to induce RNAi. 
In comparison to shRNAs designed to bypass Drosha processing, shRNA-miRs (such 
as the TRIPZ library based upon the miRNA-30 backbone) are meant to undergo all 
endogenous miRNA processing steps. In the case of TRIPZ, the asymmetric bulge present in 
21 
endogenous miR-30 was not transferred to exogenous RNAi usage, but the flexible miR-30 
loop and basal stem 5’ and 3’ Drosha flanking regions were, enhancing optimal Dicer and 
Drosha processing. This overall structure of perfect stem + flanks + loop has been found to 
trump traditional shRNA structures’ potency, producing >12-fold more guide strand, 
particularly in the single-copy integrant context, and is commercially available as the 
TRIPZ/GIPZ library from OpenBiosystems (Zeng et al. 2002; Zhang and Zeng 2010; Zeng 
and Cullen 2003; Boden et al. 2004; Stegmeier et al. 2005; Chang et al. 2006; Silva et al. 
2005). 
An alternate miRNA backbone for shRNAs, miR-155/BIC allowed for intron-
localization of shRNAmirs within a protein marker, as well as poly-cistronic production of 
up to eight tandem copies of shRNAs. However, in comparison to the miR-30 shRNAmir 
adaptation libraries, the stem structure of miR-155 was preserved for subsequent usage, 
maintaining a 5:3 asymmetric bulge in the center portion of the miRNA-shRNA stem for 
these 5P guide strands. These RNAPII-transcribed shRNAs are marketed, by Thermo Fisher 
Scientific under the BLOCK-iT brand, to be equally capable of repressing targets vs 
traditional RNAPIII-transcribed shRNAs (Chung et al. 2006). 
Lower levels of transcription, miRNA loops, and Drosha-substrate flanks are all 
components of increased potency and/or reduced toxicity. Unlike shRNAs and siRNAs, 
shRNAmirs do not observably compete with endogenous miRNAs for transport and RISC 
incorporation (Castanotto et al. 2007). Dosed to produce the same level of RNAi activity, 
shRNAmirs are better tolerated vs. shRNAs, an example of the value of undergoing 
traditional processing events. Merely reducing transcription levels is not a cure-all: a weaker 
RNAPIII promoter, H1 (vs. U6), still promotes pre-miRNA build-up and toxicity in vivo 
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(Boudreau et al. 2008b). Maintaining the same high level of U6/RNAPIII transcription 
throughout the set of experiments, two active, toxic shRNAs maintained activity but lost 
toxicity when guide/passenger strands were embedded in a Drosha-substrate & miRNA loop 
context (McBride et al. 2008). Endogenous miRNA loop sequences by themselves increase 
processing efficiency (Hinton et al. 2008). The loop, bulged stems, and Drosha-substrate 
flanks in a polycistronic context, achieve for the shRNAmir the same level of knockdown as 
shRNA guide strands present at 15-30-fold higher levels (Liu et al. 2008). 
Thermodynamically unstable stems, whether obtained via bulged/mismatched 
basepairs, or G:U wobble pairing, are miRNA-like structures; recommendations of their 
incorporation into shRNAs creates an shRNAmir. A random nucleotide library produced a 
structure with 3 mismatch bulges along its stem that were critical for activity (Wang et al. 
2008a). In a different setting, mismatches at positions 1, 4, and 10, starting from the 5’ 
phosphate, increased shRNA activity vs. perfectly stemmed precursors (Wu et al. 2011). 
Bulged stem shRNAmirs as part of bi-functional shRNAs, have been combined with 
traditional stem structure shRNAmirs, resulting in increases in potency, durability, and in 
vivo use without toxicity (Rao et al. 2010; Phadke et al. 2011). 
Within the miR-30 backbone, though a recent report ended up recommending 
optimization of the Drosha substrate region for increased efficacy due to increased ease of 
adoption, the authors also found that the replacement of the endogenous asymmetric bulge 
back into miR-30 based shRNAmirs greatly increased RNAi activity (Fellmann et al. 2013). 
Elsewhere, a miR-30-based shRNA optimization paper wanted to take the backbone back to 
their roots, placing the guide strand back on the 5P strand, re-introducing the stem central 
symmetric bulge, and adding another bulge at position 4 paper, alterations that improved 
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RNAi activity (Zeng et al. 2013). These observations in addition to those in Chapter 2 
produce an aggregate recommendation: return to miRNA-like stem structures, in addition to 
the loop and flank modifications, for optimal shRNAmir activity. 
So why would thermodynamic instability be of positive benefit? Some of it has to do 
with enhanced processing and unwinding of the passenger from the guide strand, but there is 
also a contribution from Dicer-independent biogenesis that we will discuss in the next 
section. One perspective is that stem central bulges or G:U basepairs assist in Ago1/3/4 
unwinding, the rate limiting step in RISC activation for these Ago proteins. With or without a 
single nucleotide central bulge in the stem, shRNAs associate with Ago1-4 indiscriminately, 
so Ago 1/3/4 might be clogged with perfectly stemmed RNA duplexes, resistant to 
unwinding and activation of RISC (Gu et al. 2011). It is interesting to note that this clogging 
was verified elsewhere with perfectly stemmed precursor saturating Ago3, indicating an 
Ago2 cleavage requirement for optimal RISC maturation of perfectly stemmed precursors 
(Yang et al. 2012). 
We have learned a lot about how to take an shRNA and move it through the canonical 
endogenous miRNA processing pathway with as high processing efficiency and low toxicity 
as possible, primarily through the incorporation of Drosha substrate flanks and endogenous 
miRNA loops. Though mismatches in the stem have been recommended, their adoption by 
the community is far from overwhelming. Together, these developments in shRNAmir 
technology allow single-copy integration events to compete with the toxically saturating 
levels of RNAi activity produced by first generation shRNAs.  
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Dicer-Independent Biogenesis and AgoshRNAs 
Previously, Ago2 was known to have the following activities: it bound the guide 
strand, it cleaved target mRNA, it repressed translation, it cleaved siRNA passenger strands 
for RISC maturation, if the stem central region was perfectly complementary, and it 
produced ac-cleaved pre-miRNA in very limited cases. Now we will learn of necessary non-
canonical processing by Ago2 of an endogenous miRNA precursor. Though discovery of the 
non-canonical biogenesis pathway has produced a new mechanism by which to harness 
RNAi, it is also the likely culprit behind some of the inefficiencies that we report for 
shRNAmirs and shRNAs in Chapters 2 and 3. 
In a surprising state of affairs, an endogenous microRNA that is processed by Drosha 
skips Dicer processing, instead maturing via Ago2. A precursor depositing complex surveys 
the precursor for Dicer processing compatibility (an abundance of stem mismatches induce 
the Dicer pathway) vs. potential mid-stem cleavage by Ago2 (perfectly complementary stems 
induce this pathway). Ago2 cleaves the 3P as if it were a passenger or target mRNA, and the 
terminal end is further trimmed to the loop by the poly(A)-specific ribonuclease, such that 
the 17nt 5’ arm + 4nt loop combine to become the guide strand. This Dicer-independent 
miRNA precursor stands out amongst other endogenous microRNA precursors in that it 
looks similar to shRNAs in some aspects. Though shorter than an shRNA (17nt stem, too 
short for efficient Dicer processing), pre-miR-451 contains no mismatches in its stem. 
Introduction of a bulge at the site of Ago2 cleavage inhibits mature miR-451 production by 
Ago2. The miR-451 secondary structure can carry other sequences through the Dicer-
independent pathway, much as the miR-30 backbone was intended to carry sequences 
through Dicer. Though processed at a lower efficiency compared with Dicer, potency may be 
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higher than Dicer-specific shRNAs due to Ago2-specificity (Cheloufi et al. 2010; Cifuentes 
et al. 2010; Yang et al. 2010; Dueck et al. 2012; Herrera-Carrillo et al. 2014, 2015; Liu et al. 
2015a, 2013; Yoda et al. 2013; Liu et al. 2012) (Figure 1.2). 
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Figure 1.2 Dicer-independent miRNA biogenesis. Drosha and DGCR8 process the 
secondary structure as in the canonical pathway. The pre-miRNA transits the nuclear pore 
complex via Exportin-5, however Dicer-independent biogenesis requires a 
thermodynamically stem, optimally shorter so as to not compete with Dicer processing, i.e. 
~17 basepairs in length. Short length + stability allow Ago2 to produce an ac-pre-miRNA, 
cleaving the 3P strand opposite nucleotides 10/11 of the 5P strand. The remainder of the 3P 
strand is recessed to the loop by PARN, after which the entirety of the 5P strand + the loop 
become the guide strand for Ago2. No other Ago proteins incorporate miR-451, because 
Ago2 is the only enzyme with slicing ability, and miR-451 is too short to transit the Dicer 
pathway. 
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AgoshRNAs and 5P guide strand short shRNAs (sshRNAs) are the different terms for 
shRNA variants that prefer the Dicer-independent pathway, but can be inefficiently 
processed by Dicer as well. Much as the guide strand of miR-451 is on the 5P, guide strands 
for sshRNAs are of increased potency if they arise from the 5P. Also similar to miR-451, 
mismatches in sshRNA stems reduces efficacy, but this effect does not inhibit efficacy if the 
stem is lengthened (to again mimic an shRNAmir and traverse the Dicer pathway). 
Additionally, placement of the guide strand on the 3P requires loop cleavage (Dicer 
maturation) for optimal activity, while 5P guide strands do not (Ago2 maturation) (Ge et al. 
2010; Dallas et al. 2012).  
miR-451 biogenesis can be disrupted through thermodynamic instability/central-stem 
mismatches. Though it is established that Dicer can inefficiently process AgoshRNAs, and 
Ago-2 can inefficiently process shRNAs, mainly due to stem length, negative effects of the 
Dicer-independent pathway on shRNAs and shRNAmirs have yet to be linked. A few hints 
exist; Dicer is definitely bypassed by some shRNAs, with RISC incorporation occurring in 
unintended ways (a portion of the 5’ arm, the loop, a portion of the 3’ arm, for example). A 
single RNAPIII TRC pLKO hairpin silenced six genes in addition to its target, due to 
inappropriate cleavage/maturation ending up in RISC, silencing targets (Bhinder et al. 
2014b). In Drosophila, Dicer depletion results in guide strand variability increases including 
miR-451-like loci (Yang et al. 2014). Together, these observations point to the possibility 
that Dicer-independent biogenesis may affect shRNAs, not only inhibiting their own potency, 
but also dysregulating endogenous miRNA levels.  
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Chapter 2: Optimizing short hairpin RNA design to maximize RISC loading 
Overview 
Gene silencing via short hairpin mediated RNAi (shRNA) is a valuable experimental 
tool.  One of the most popular shRNA platforms makes use of the loop and flanking 
sequences from the endogenous microRNA (miRNAs) miR-30a to provide an RNA structure 
for efficient biogenesis of the RNA trigger.  However, the stem regions of these shRNAs are 
designed as perfect duplex structures which is an uncommon feature for endogenous miRNA 
precursors. Here, we report that shRNAs with perfect duplex stems undergo extensive stem 
cleavage analogous to the Dicer independent miRNA miR-451.  This cleavage event destroys 
the shRNA trigger sequence that is present in the 3P arm.  We employed an unbiased screen 
of shRNA structures to identify features that prevent stem cleavage and promote canonical 
biogenesis and loading into the effector complex RISC.  We find that a central stem bulge in 
addition to a secondary bulge is an optimized structure for shRNA efficiency. 
 
Introduction 
RNA interference (RNAi) is a widely used technology to study gene function 
(Hannon and Rossi 2004; Mohr and Perrimon 2012; Kaelin 2012). Broadly, RNAi can be 
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divided into two experimental approaches based on the form of the gene silencing trigger. 
siRNAs are short duplex RNAs that are transiently transfected into the experimental cell line. 
After incorporation into the RNA induced silencing complex (RISC), the guide strand of the 
siRNA directs RISC to complementary target RNAs and promotes silencing of the target 
gene. This form of RNAi is relatively short lived due to the transient nature of the siRNA 
trigger. In contrast, plasmid encoded shRNA triggers are capable of long term gene silencing. 
shRNAs are stem-loop RNAs that require cellular biogenesis pathways prior to RISC 
loading. shRNA expression systems based on retroviral vectors are especially valuable since 
they can be used for silencing gene expression long-term in cells refractory to transient 
transfection.  
shRNA expression vectors are based on two general designs. The original shRNA 
vectors used the U6 or H1 promoter to drive expression of a stem loop RNA with a 19 or 29 
nucleotide stem and a small loop (Moffat et al. 2006; Bernards et al. 2006; Paddison et al. 
2002; Brummelkamp et al. 2002). These RNAs resemble miRNA precursors and are directly 
processed by the miRNA biogenesis enzyme Dicer prior to RISC loading. More recent vector 
designs have the shRNA trigger embedded in the loop and flanking sequences of miR-30a 
(shRNAmir) (Zeng et al. 2002; Stegmeier et al. 2005; Silva et al. 2005). This shRNA 
transcript resembles a miRNA primary transcript and requires Drosha and Dicer processing 
prior to RISC loading.  shRNAmirs are typically expressed from a RNA polymerase II 
promoter and therefore allow the use of the full complement of regulatable mammalian 
promoter systems.  Additionally, the lower transcription rate of RNA polymerase II 
promoters and more natural loop and flanking regions result in reduced toxicity of the RNA 
compared to U6 based shRNA vector systems (Sun et al. 2013; Ahn et al. 2011; Shimizu et 
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al. 2009; Boudreau et al. 2008a; McBride et al. 2008; Castanotto et al. 2007).  Notably, both 
vector designs frequently place the shRNA trigger sequence on the bottom of the stem loop 
(3P strand) for more accurate and biogenesis cleavage products.  Furthermore, both shRNA 
designs commonly maintain perfectly duplexed stem structure unlike endogenous miRNAs 
(including miR-30a).  While retroviral shRNA systems have found widespread use in 
biomedical research they often display incomplete target gene knockdown, especially when 
integrated at a single genomic copy (Fellmann et al. 2011, 2013; Premsrirut et al. 2011). 
We have previously developed next generation sequencing technologies for the study 
of miRNA biogenesis (Newman et al. 2011).  Here, we applied these approaches to the 
analysis of shRNA biogenesis.  We find that the vast majority of shRNA precursors are 
internally cut on the 3P stem analogous to the Dicer-independent miRNA miR-451.  Since 
shRNA vector systems are designed with the gene silencing trigger on the 3P strand, this 
cleavage will limit the amount of trigger RNA that can be loaded into RISC.  To improve 
shRNA biogenesis efficiency we developed an unbiased screen to identify structural features 
that promote Dicer processing and RISC loading.  We report that central mismatches are 
essential to prevent internal 3P cleavage and that an additional mismatch improves shRNA 
yield and knockdown potential. 
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Materials and Methods 
Cell culture, transfection, and transduction 
3T3 fibroblasts were cultured as described by ATCC.org.  Cells were transduced with 
TRIPZ as described by Dharmacon, using 1:3 serial dilutions into 6-well plates to obtain 
single-copy MOI.  Cells were selected and maintained in 1.25 ug/ml puromycin.  1 x 105 
cells were plated in 24-well format on Day 1 of a reporter assay; shRNAmir expression was 
induced after cell attachment with 1 ug/ml doxycycline (replenished every 24 hours until 
lysate harvest).  On Day 2, psiCHECK 2.0 constructs were transfected using Lipofectamine 
2000.  On Day 3, media was changed, and the lysate was harvested on Day 4 using Promega 
Passive Lysis Buffer.  For co-transfection studies, 1ug/ml doxycycline was present during 
transfection of both the TRIPZ and psiCHECK 2.0 plasmids, otherwise usage was identical 
to Day 3 onward of the transduction protocol.  All luciferase assays within a single panel of a 
figure compare single-copy integrants of the same passage number (i.e. control, parental, and 
experimental shRNAs were transduced side by side), and exposed to doxycycline and 
puromycin premixed prior to use into a common source.  Error bars are the standard 
deviation of technical replicates of three independent transfections of reporter. 
Constructs 
Appropriate perfectly complementary 1X targets were designed to anneal and 
produce sticky ends ready for psiCHECK 2.0 XhoI/NotI.  Guide and passenger strand 
sequences were obtained from the RNAi Consortium, pLKO.1-based plasmids 
TRCN0000090506 (Col1A1) and TRCN0000254936 (Fox3).  These sequences were 
transferred to the miR-30/TRIPZ backbone, amplified with 5’ and 3’ primers containing 
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EcoRI/XhoI sites, and ligated into TRIPZ.  To maintain desired secondary structure while 
still producing identical 3’ guide strands throughout, sequence variants that transferred 
responsibility for this structure to the 5’ passenger strand were verified by RNAfold (Gruber 
et al. 2008; Lorenz et al. 2011).  All shRNAmir and reporter oligonucleotides used can be 
found in S1 Table.  
High-throughput deep sequencing and analysis 
Precursor-specific deep sequencing was performed as previously described (Newman 
et al. 2011).  Ago-associated RNA were immunopurified using Protein A Dynabeads (Life 
Technologies) and the 2A8 antibody, preferential for Ago2 (Diagenode).  RNA was extracted 
using Trizol (Invitrogen).  Small RNA deep sequencing libraries originated from 5.0 ug total 
RNA using a method similar to that previously published (Pfeffer et al. 2005).  Briefly, a 3’ 
adapter was ligated to total RNA using truncated RNA ligase 2, which was then size 
extracted (retaining 40-60nt products of linker + small RNA and removing excess 3’ adapter) 
on a 12.5% 8M urea polyacrylamide gel.  T4 RNA ligase 1 attached a 5’ adapter containing a 
two nt barcode.  After reverse transcription and PCR amplification, these barcodes allowed 
multiplexing prior to sequencing on a HiSeq 2000 (Illumina).  Primers that amplified the 
flanking regions of shRNAs were used to verify plasmid library screen depth, as well as to 
identify and quantify genomic integrants in the population for normalization; see S1 Table. 
Raw sequence reads were processed using a custom bioinformatics pipeline (Newman 
et al. 2011).  Precursor reads were mapped according to terminal nucleotide position.  Mature 
shRNAs from the library screen were mapped to the originating structural variant.  Reads for 
each variant were normalized to the amount of integrated provirus for that variant. 
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Results 
We investigated the production of mature shRNA triggers from the widely used 
TRIPZ retroviral vector.  This vector has the shRNA duplex sequence within the context of 
the miR-30a loop and flanking sequences.  Transcription is driven from a tetracycline 
inducible promoter; see plasmid map in Figure 2.1.  We studied two moderately weak 
shRNAs that target the Col1A1 and Fox3 mRNAs.  Single copy integration into NIH-3T3 
cells led to 51 and 43% knockdown, respectively, for the two shRNAs (Figure 2.2A).  As 
expected, introduction of additional copies of the shRNA vector by transient transfection 
improved target gene knockdown.  We prepared small RNA libraries for next generation 
sequencing to quantify the amount of mature shRNA trigger present in stably expressing 
cells.  We observed 1521 and 185 reads per million for the Col1A1 and Fox3 shRNAs, 
respectively, in cells with single copy integration of the corresponding TRIPZ vector.  These 
reads are in contrast to endogenous miRNAs that in some cases had 100 fold more mature 
sequence reads.  Notably, miR-21a is a miRNA present at a single genomic locus yet had 
greater than 200,000 normalized sequence reads. 
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Figure 2.1. pTRIPZ plasmid map. 5’LTR and SIN-LTR are long terminal repeats; SIN-
LTR is self-inactivating. The Tetracycline-response element contains 5 tet operators and a 
minimal CMV promoter; the miR-30 based shRNAmir is embedded in the 3’ UTR of turbo 
RFP. Bacteria are cultured in Carbenecillin and Zeocin; cells are cultured in Puromycin. 
(Adapted from Dharmacon Technical Manual) 
 
We next sought to identify causes for the low yield of mature shRNA trigger in virus 
transduced cells.  We employed a previously developed deep sequencing approach specific 
for miRNA precursors.  This approach provides not only read counts for specific precursor 
sequences but also provides information about internal 3P stem cleavage, trimming, and 
nontemplated nucleotide addition.  For example, analysis of precursor reads for the miRNA 
Let-7g demonstrates that almost all precursors are full length sequences, with < 1 percent of 
the sequences trimmed and/or cut internally in the 3P stem or near the loop (Figure 2.2C, 
blue bars).  Let-7a1 has a greater fraction of precursors that are cleaved internally; however, 
most precursors remain full length.  The increase in internal cleavage for Let-7a1 is likely 
due to the perfect duplex structure of the stem-loop, a feature known to promote Ago2 
mediated cleavage. 
 
35 
 
 
Figure 2.2. Stem cleavage reduces biogenesis efficiency of shRNAs.  (A) Knockdown 
activity for two different shRNAs was determined using a luciferase reporter vector.  NIH-
3T3 cells were stably transduced with shRNA retrovirus at single copy integration and target 
knockdown measured.  Multi-copy knockdown was determined by transient transfection of 
additional shRNA vector into cells.  (B) Small RNAs from shRNA transduced cells were 
sequenced using the Illumina platform.  Normalized miRNA and shRNA reads are plotted in 
rank order.  (C) Precursor miRNAs and shRNAs were sequenced using a customized 
Illumina protocol.  Read counts for individual miRNAs/shRNAs were counted for each 
terminal nucleotide position on the precursor sequence.  The height of each blue bar indicates 
the relative read count for precursors that terminate at the indicated 3' position.  Three 
representative miRNAs are shown along with the shRNAs. 
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We then analyzed precursor reads for the two shRNAs.  Over 99 percent of reads had 
evidence of internal cleavage and trimming.  This cleavage pattern is reminiscent of the 
Dicer independent miR-451 biogenesis and may be related to a recently reported Ago2-based 
precursor surveillance system (Cheloufi et al. 2010; Cifuentes et al. 2010; Yang et al. 2010; 
Liu et al. 2012, 2014).  Notably, the endogenous precursor for miR-30a, which the TRIPZ 
system is based on, contains an asymmetric bulge at nucleotides 12/13 of the 5P arm and is 
resistant to internal cleavage.  However, when the miR-30a precursor was adapted to the 
shRNA vector system the central stem bulge was not retained; only the loop and flanking 
sequences were retained.  The stem region of these shRNAs are perfect duplexes and 
therefore substrates of internal Ago2 cleavage, a critical problem, since the trigger strand is 
the 3P strand of the stem.  Any internal cleavage will destroy the trigger, reducing potency 
and potentially increasing incorporation of the 5P strand with concomitant off-target effects. 
It should be noted that trigger strand cleavage is not only observed with TRIPZ.  We find 
extensive cleavage with the U6 based pLKO vector - which also has a perfect duplex stem 
(data not shown). 
To directly test whether the perfect duplex stem was promoting internal cleavage we 
modified the shRNA vector to include a central bulge in the duplex region in the range of 
positions 9-11, positions that inhibit Ago2 cleavage of siRNA passenger strands, target 
mRNAs, and miR-451 biogenesis (Martinez et al. 2002; Matranga et al. 2005; Elbashir et al. 
2001; Cifuentes et al. 2010; Yang et al. 2010; Leuschner et al. 2006).  We introduced these 
mismatches in the 5P non-trigger strand of both the Col1A1 and Fox3 shRNA vectors.  The 
3P trigger sequence was unchanged to allow direct comparison to the original structure.  
Precursor sequencing of these modified shRNAs demonstrated that > 99 percent of reads 
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were full length with very limited internal cleavage (Figure 2.3A).  We directly compared 
knockdown efficiency of the stem-bulged shRNAs with perfect duplex shRNAs.  At single 
copy integration, bulged shRNAs led to increased knockdown potency (Figure 2.3B). 
 
 
 
Figure 2.3 shRNA stem-central bulges prevent internal cleavage and promote 
knockdown activity.  (A) Mutations were introduced into precursor sequences to create a 
central bulge in the stem loop structure.  A single-nucleotide bulge at #9, counting from the 
5' terminal end, and two nucleotide bulges at #10/11 were introduced in the 5P arm to allow 
identical trigger sequences.  Precursor shRNAs were sequenced and read counts for 
individual shRNAs were counted for each terminal nucleotide position on the precursor 
sequence.  The height of each blue bar indicates the relative read count for precursors that 
terminate at the indicated 3' position.  (B) Knockdown activity was determined of mutant 
shRNAs structures from (A).  shRNAs were transduced at single copy and reporter activity 
measured. Asterisk indicates statistical significance of difference in activity compared to WT 
shRNA (P < .05, Mann-Whitney-U test). 
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While these rational design changes improved shRNA performance, we wanted to 
identify other structural features that would further optimize shRNA biogenesis and RISC 
loading.  To this end we devised a non-biased screen to identify optimal shRNA structures 
(Fig 2.4A).  Through the use of degenerate nucleotides, we generated a library of different 
shRNA structures around the Col1A1 and Fox3 shRNA sequences within the TRIPZ vector.  
These structures included central bulge options at stem positions 9-11 counting from the 5’ 
precursor phosphate.  Since all three positions were degenerate, the library contains non-
bulged structures as well as single, double, and triple mismatch-containing bulges. We also 
wanted to determine whether additional miRNA precursor-like characteristics would increase 
shRNA trigger loading.  Therefore, libraries included a degenerate nucleotide at position 19, 
allowing a single nucleotide bulge at the Dicer cleavage site.  Libraries also included 
degenerate nucleotides allowing an additional bulge 3' and 5' of the central bulge.  These 
additional bulges could be mismatches (MM), G:U base pairs, or could be WT (non-bulged).  
All degenerate nucleotides were introduced on the 3P trigger strand; the 5P strand was 
unaltered for all structures (Fig 2.4B).  We introduced this library of 144 possible structures 
for each shRNA into NIH-3T3 cells by retroviral transduction.  To identify structural variants 
that enhanced biogenesis and RISC loading, we isolated Ago2 associated RNAs by 
immunoprecipitation, and identified enriched degenerate nucleotide structures, normalized to 
the sequenced provirus population. 
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Figure 2.4. Unbiased screen for optimized shRNA structures.  (A) The flow chart for our 
shRNA structure screen is shown.  Randomized shRNA structures were generated using 
degenerate oligonucleotides and were cloned into the TRIPZ vector backbone.  Structure 
libraries were packaged into virus and transduced into NIH-3T3 cells.  Ago2 associated small 
RNAs were isolated and identified by deep sequencing.  Optimal structures were identified 
by normalizing deep sequencing reads of Ago-associated guide strands to provirus reads.  (B) 
The structural variants in the library are illustrated and compared to an abundant miRNA 
precursor. 
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The most striking feature of enriched shRNAs was a central bulged sequence.  Figure 
2.5A displays fold enrichment of shRNA structures containing specific central bulges.  Each 
bar represents the average enrichment of the 18 structures in the library that contain that 
specific central bulge (3x3x2 structures for 5' and 3' flanking bulge/GU and Dicer bulge).  
Therefore, some individual structures with the indicated central bulge have a greater 
enrichment than shown since some structures were heavily disfavored.  Also worth nothing 
within this panel, the WT bars in the graph (non-bulged) show enrichment > 1 due to the 
favorable effects of flanking bulges increasing the average for the entire bin.  A direct 
comparison of each central bulge position when all other degenerate positions were wild type 
is shown in the supplement (Figure 2.S1A). 
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Figure 2.5. Optimized shRNA structures and activity.  (A) Ago-associated shRNAs were 
sequenced to determine the optimal structures for biogenesis and RISC loading.  Structural 
variants were binned by type of central mismatch and average fold enrichment versus full 
wild type sequence is shown. Asterisk indicates significance compared to WT central stem 
bulge, P < .05,  student’s paired two-tailed t-test. (B) Structural variants with a mismatch at 
nucleotide position #9 were further binned by 5' and 3' flanking mismatch variant.  Fold 
enrichment of read counts versus full wild type is shown.  (C) Illustration of precursor 
structures that are presented in the figure. (D) Knockdown efficiency of enriched structural 
variants.  shRNA structures were cloned by moving the indicated mismatches into the 5P 
stem, allowing identical trigger sequences.  shRNAs were transduced into NIH-3T3 cells at 
single copy and knockdown determined by reporter gene activity. A single asterisk indicates 
statistical significance of difference in activity compared to WT shRNA; two asterisks 
indicate significance compared to both WT shRNA and shRNAs with only central-stem 
bulges (P < .05, Mann-Whitney-U test). 
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Immunoprecipitation of Ago-associated reads revealed a preference for a bulge for 
the Col1A1 and Fox3 shRNAs at nucleotides 9 and 10, though the Col1A1 shRNA was 
optimal with a single nucleotide bulge at 9, while the Fox3 shRNA was optimal with a 
double nucleotide bulge at 9/10. Adding a flanking bulge provided modest further 
enrichment in Ago2 associated shRNAs, though the two shRNAs differed in the preferred 
location of the flanking second bulge.  The Col1A1 shRNA preferred a second bulge 5' to the 
central bulge while the Fox3 shRNA preferred a second bulge on the 3' flank in addition to a 
5’ G:U. Disparities here likely have to do with the relative thermodynamic stabilities of each 
shRNA sequence’s 5’ end competing with the benefits of inhibited slicing activity, but 
overall agree with structural determinants for endogenous miRNA RISC loading and slicer-
independent unwinding (Schwarz et al. 2003; Kawamata et al. 2009). 
 Structures are illustrated in Figure 2.5C.  Bulges very close to the Dicer cleavage site 
were strongly disfavored (not shown), supported by previous reports of Dicer promiscuity 
induced when the intended cleavage site is within 2 nucleotide of a loop or bulge (Gu et al. 
2012). 
shRNA structural improvements were validated by reporter knockdown analysis.  The 
enriched shRNA structures were recapitulated by switching the mismatch to the 5P arm to 
allow a common WT 3P trigger sequence.  Both the Col1A1 and Fox3 shRNA vectors were 
modified to contain the same structural alterations.  Retroviral vectors were transduced into 
NIH-3T3 cells at single copy MOI and knockdown determined by reporter gene expression.  
Structural features that lead to increased enrichment by Ago2 associated deep sequencing 
also provided improved knockdown (Figure 2.5D).  Notably, both shRNAs were improved 
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by the same structural alterations even though their preferences as reported by the screen 
were slightly different.  
 
Discussion 
In this report we describe extensive internal cleavage and trimming of shRNA 
precursors.  The cleavage is likely due to direct endonucleolytic action of Ago2 on the 
shRNA precursor.  The Dicer independent miRNA miR-451 is processed by Ago2; several 
miRNAs have been reported to be cut in the 3P stem at some frequency (Cheloufi et al. 2010; 
Cifuentes et al. 2010; Yang et al. 2010; Diederichs and Haber 2007).  Interestingly, 
incompletely trimmed miR-451 (up to 30nt in length after Ago2 cleavage), retains RNAi 
activity (Yoda et al. 2013).  Regardless of how much of the remaining non-canonically 
processed precursor maintains activity, many have used this discovery to circumvent Dicer 
processing, using the miR-451 structure as a template for alternatively processed shRNAs 
(AgoshRNAs) carrying 5P+loop guide strands (Ge et al. 2010; Dallas et al. 2012; Liu et al. 
2013; Ma et al. 2014b; Herrera-Carrillo et al. 2014; Yang et al. 2012; Liu et al. 2015a).  
Ago2 cleavage of precursors is dependent on a perfect duplex stem, a feature that is absent in 
most endogenous miRNA precursors.  In the case of miR-451, Ago2 cleavage of the 3P stem 
can lead to productive mature miRNA, since the mature strand is on the 5P stem.  The most 
common shRNA vector designs, however, place the active shRNA trigger on the 3P stem.  
Thus, Ago2 cleavage would destroy the trigger and compromise the potency of the shRNA.  
While the structural features that promote Ago2 cleavage of precursors has been known, our 
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deep sequencing results described herein demonstrate the extent of precursor loss and 
resultant inefficiency of conventional shRNA designs. 
Several groups have used rational design to improve shRNA structures for increased 
target gene knockdown.  Stem mismatches have been previously reported to increase 
knockdown potency (Wang et al. 2008b; Wu et al. 2011; Zeng et al. 2013; Rao et al. 2010).  
The stem bulges have been hypothesized to decrease Ago2 cleavage and/or to decrease 
thermodynamic pairing energy.  Asymmetric mutations in the stem leads to a kinked and 
bulged structure that reduces accuracy of Dicer cleavage (Starega-Roslan et al. 2011).  G:U 
wobble basepairs have also been described in stems to promote Dicer processing, may have 
the same effect as bulges when it comes to guide:passenger strand selection, and have been 
reported to inhibit AgoshRNA activity (Okamura et al. 2009; Gu et al. 2011; Liu et al. 
2015b).  While these improvements have been demonstrated, the adoption of these design 
changes to commercial shRNA vector systems has been slow.  The miR-30-based TRIPZ 
vector as well as U6 based vectors (pLKO from the RNAi Consortium) are still designed 
with perfect duplex stems.  One reason for the resistance to new structures is that shRNA 
libraries would need to be redeveloped.  Furthermore, it is not clear that previous studies 
were able to maximize the design improvement due to the rational method of design changes. 
The unbiased structure library screen that we report here uncovers an optimized structure 
based on RISC loading enrichment. 
In addition to increases in knockdown potency, reduction in Ago2 precursor cleavage 
may reduce unwanted off-target effects (Bhinder et al. 2014b).  Small RNAs processed in 
unintended ways from a traditional shRNA currently in clinical trials parallel the sequences 
we observe in precursor-specific deep sequencing; surely an antisense drug would be 
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preferable if it only traversed one biogenesis pathway instead of two (Denise et al. 2014). 
Ago2/RISC activity has been reported to arise directly from pre-let-7a-3 without Dicer 
presence (Tan et al. 2009, 2011).  Interestingly, Dicer depletion in Drosophila increased 
levels of Dicer-independent processing of miRNA precursors (Yang et al. 2014).  If 
unintended Ago2 cleavage and subsequent RISC incorporation of shRNAs contributes to off-
target effects, expression of shRNAs may be exacerbating these effects through Dicer 
saturation.  It has been previously established that shRNAs can compete with miRNAs for 
export to the cytoplasm, and that shRNA toxicity can arise via saturation of the endogenous 
miRNA biogenesis pathway (Grimm et al. 2006, 2010; Boudreau et al. 2008a).  It is 
interesting to speculate that saturation of Ago2 with perfectly duplexed shRNA may 
contribute in novel ways to shRNA toxicity, off-target effects, and/or miRNA pathway 
alterations.  
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Figure. 2.S1 Additional structural preferences identified in screen. (A) Optimal structural 
variants, identified by enrichment of Ago-associated reads in comparison to provirus reads; 
bins here are all 5’ and 3’ WT flanks, such that the only variation is in the central-stem 
mismatch, and the WT bin would therefore be identical to the traditional TRIPZ structure. 
(B) Structural variants with a mismatch at nucleotide positions #10/11 were further binned by 
5’ and 3’ flanking mismatch variant. Fold enrichment of read counts versus flanking wild 
type is shown. 
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 Table 2.1: Cloning Oligonucleotides  
All primers listed in 5' to 3' orientation. Italic = miR30 loop. Bold = miR30 flanking sequence. Lower case = non-WT nucleotide. 
Amplification primers 
5'miR30-XhoI TACAATACTCGAGAAGGTATATTGCTGTTGACAGTGAGCG 
3'miR30-EcoRTI ACTTAGAAGAATTCCGAGGCAGTAGGCA 
Perfect and centrally-bulged stems 
Col1A1 WT GGTATATTGCTGTTGACAGTGAGCGCCGAGGTATGCTTGATCTGTATAGTGAAGCCACAGATGTATACAGATCAA
GCATACCTCGGTGCCTACTGCCTCGGAATTC 
Col1A1, bulge #9 GGTATATTGCTGTTGACAGTGAGCGCCGAGGTATGaTTGATCTGTATAGTGAAGCCACAGATGTATACAG 
Col1A1, bulge 
#10/11 
GGTATATTGCTGTTGACAGTGAGCGCCGAGGTATGCccGATCTGTATAGTGAAGCCACAGATGTATACAG 
Col1A1 rev/comp 3' 
strand 
GAATTCCGAGGCAGTAGGCACCGAGGTATGCTTGATCTGTATACATCTGTGGCTTCACTAT 
Fox3 WT GGTATATTGCTGTTGACAGTGAGCGGGATAGGTGGAGTAGGGTTAATAGTGAAGCCACAGATGTATTAACCCTAC
TCCACCTATCCTGCCTACTGCCTCGGAATTC 
Fox3, bulge #9 GGTATATTGCTGTTGACAGTGAGCGGGATAGGTGGcGTAGGGTTAATAGTGAAGCCACAGATGTATTAACC 
Fox3, bulge #10/11 GGTATATTGCTGTTGACAGTGAGCGGGATAGGTGGAagAGGGTTAATAGTGAAGCCACAGATGTATTAACC 
Fox3 rev/comp 3' 
strand 
GAATTCCGAGGCAGTAGGCAGGATAGGTGGAGTAGGGTTAATACATCTGTGGCTTCACTA 
Screen: 
Col1A1 Screen 5'+lp GGTATATTGCTGTTGACAGTGAGCGCCGAGGTATGCTTGATCTGTATAGTGAAGCCACAGATGTA 
Col1A1 Screen 3'+lp GAATTCCGAGGCAGTAGGCACCGAGdTATGykkGATCTdTmTACATCTGTGGCTTCACTATACA 
Fox3 Screen 5'+lp GGTATATTGCTGTTGACAGTGAGCGGGATAGGTGGAGTAGGGTTAATAGTGAAGCCACAGATGTA 
Fox3 Screen 3'+lp GAATTCCGAGGCAGTAGGCAGGATAdGTGGmkkAGGdTTAmTACATCTGTGGCTTCACTATTAAC 
Move screen preferences to 5' strand, amplify using Col- and Fox-specific rev/comp 3' oligos above. 
Col1A1, bulge#4/9 GGTATATTGCTGTTGACAGTGAGCGCCGAGaTATGaTTGATCTGTATAGTGAAGCCACAGATGTATACAG 
Col1A1, G:U #2, 
bulge #9/15 
GGTATATTGCTGTTGACAGTGAGCGCCGgGGTATGaTTGATaTGTATAGTGAAGCCACAGATGTATACAG 
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Col1A1, bulge 
#4/9/15 
GGTATATTGCTGTTGACAGTGAGCGCCGAGaTATGaTTGATaTGTATAGTGAAGCCACAGATGTATACAG 
Fox3, bulge #4/9 GGTATATTGCTGTTGACAGTGAGCGGGATAaGTGGcGTAGGGTTAATAGTGAAGCCACAGATGTATTAACC 
Fox3, G:U #3, bulge 
#9/15 
GGTATATTGCTGTTGACAGTGAGCGGGATgGGTGGcGTAGGaTTAATAGTGAAGCCACAGATGTATTAACC 
Fox3, bulge #4/9/15 GGTATATTGCTGTTGACAGTGAGCGGGATAaGTGGcGTAGGaTTAATAGTGAAGCCACAGATGTATTAACC 
Psicheck 2.0 
Col1A1 for/rev TCGAGCCGAGGTATGCTTGATCTGTA, GGCCTACAGATCAAGCATACCTCGGC 
Fox3 for/rev TCGAGGGATAGGTGGAGTAGGGTTAA, GGCCTTAACCCTACTCCACCTATCCC 
DEEP SEQUENCING OLIGONUCLEOTIDES (in addition to those from Newman 2011) 
shRNA precursor-specific: 
Col1A1 WT CAAGCAGAAGACGGCATACGACCGAGGTATGCTTGATCTGTA 
Fox3 WT CAAGCAGAAGACGGCATACGAGGATAGGTGGAGTAGGGTTAA 
Col1a1, bulge #9 CAAGCAGAAGACGGCATACGACCGAGGTATGATTGATCTGTA 
Fox3, bulge #10/11 CAAGCAGAAGACGGCATACGAGGATAGGTGGAAGAGGGTTAA 
Provirus normalization (nn = barcode): 
PCR2 + nn + 3' 
miR30 
AATGATACGGCGACCACCGACAGGTTCAGAGTTCTACAGTCCGACGATCnnCTTGAATTCCGAGGCAGTAGGC  
PCR1 + 5' mir30 
sense  
caagcagaagacggcatacgacttgctgggattacttcttcagg 
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 Table 2.2. Chapter 2 summary 
Pre-shRNA degradation inhibits RISC loading and activity 
 miR-30 based shRNAs are extensively degraded, reminiscent of Ago2-like 
cleavage and trimming. 
 
 Mid-stem bulges known to inhibit Ago2-cleavage of 3P strand rescue 
precursor degradation and increase shRNA potency. 
 
 Unbiased design screen reveals RISC-loading preference for miR-30 
based shRNA stem structures with weaker thermodynamics: 
o Strong preference for mid-stem bulge 
o Weaker preference for additional base-pairing disturbance 
flanking the mid-stem bulge. 
50 
 
 
 
Chapter 3: Inefficiencies Associated with RNAPIII shRNA Design 
Overview 
 Traditional shRNA structures are still in wide use, both for individual and pooled 
library knockdown gene function experiments, in addition to preclinical and clinical trials. 
Though we observe the same degradation of traditional shRNA precursors as we do for miR-
30 based shRNAs, RNAi activity is already strong due to U6-driven RNAPIII transcription, 
and unaffected by degradation-inhibiting mid-stem bulges. Additionally, we find that the 
oligouridine tail, which terminates transcription of a traditional shRNA, is incorporated into 
guide strands, inhibits processing of precursors, and induces precursor degradation. Finally, 
we observe dysregulation of the precursor surveillance system in the presence of traditional 
shRNA expression: endogenous precursor oligouridylation levels increase and trimming 
decreases. Overall, these data extend the depth of knowledge surrounding traditional shRNA 
processing, as well as downstream negative consequences associated with endogenous 
miRNA precursor surveillance. 
 
Introduction 
Traditional shRNA-mediated RNAi was a hop and a skip in tool development away 
from siRNAs, ~21 nucleotide RNA duplexes that bypasses upstream processing machinery to 
directly interact with Ago2 upon transfection, after which the intended inactive passenger 
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strands were cleaved and dissociated. However, transfection is time-limited, and not 
compatible with all cell types (Wang, 2009). Traditional shRNAs were engineered by 
connecting the 5P to 3P siRNA RNA strands via a 4-6 nucleotide loop allowed transcription 
by cell machinery, extending the amount of time available to maintain knockdown, and 
expanding potential knockdown environments in tissue culture and in vivo via transduction of 
cells previously refractory to transfection. However, this tool is only active after multiple 
biogenesis steps between introduction of the shRNA and activity, steps during which shRNA 
competes with endogenous RNAi species, promoting inefficient biogenesis of both, and in 
some cases inducing toxicity. Because the endogenous RNAi machinery is occupied, 
endogenous mRNAs normally repressed by endogenous miRNAs can be released in the 
presence of shRNA, high levels of precursor shRNAs can be transcribed but unprocessed, 
overloading the capacity of Exportin-5, Dicer, and the Ago proteins, provoking toxicity 
(Grimm et al. 2006, 2010; Beer et al. 2009). 
These traditional shRNA expression vectors are based on two general designs, both 
without bulges, and still in use today, even though bulged precursors can produce similar 
levels of knockdown via Agos1-4, while perfectly stemmed precursors are limited to optimal 
activity in Ago1/2 (Paddison et al. 2002; Brummelkamp et al. 2002; Su et al. 2009). Three 
recent papers reveal the efficiencies of traditional shRNA design: heterogeneity of 
transcription initiation positioning, Dicer-independent unintended positioning of processed 
products, and off-target effects due to this unintended processing (Bhinder et al. 2014b; 
Denise et al. 2014; Ma et al. 2014a). Alternatively, Dicer maturation can be circumvented via 
the miR-451 biogenesis pathway, limiting the guide strand activity to Ago2 (Liu et al. 2015b; 
Herrera-Carrillo et al. 2014, 2015; Liu et al. 2015a; Yang et al. 2010, 2012; Liu et al. 2013). 
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Transcription of traditional shRNAs terminates at a five thymidine termination 
sequence, generating a shortened transcript intended to skip the first step of endogenous 
miRNA biogenesis, Drosha cleavage. Of interest is the transcript’s oligouridine tail, a 
substrate for DIS3L exonuclease activity discovered in the post-transcriptional repression of 
mature let-7 processing (Ustianenko et al. 2013). An oligouridine tail of ~20 nucleotides in 
length was also previously reported to inhibit Dicer processing of let-7; what impact would 
this oligouridine tail have on processing (Heo et al. 2009)? Additionally, a recently reported 
precursor surveillance system, separate from the Lin28/let-7 regulatory pathway, checks for 
appropriate 3’-OH overhang length. Exosome component RRP6 degrades shorter overhangs, 
while DIS3 degrades longer overhangs that can be added by TUT-4/7, repressing guide 
strand expression levels (Liu et al. 2014). 
Here, we use precursor-specific deep sequencing as previously mentioned to observe 
the same high levels of slicing and trimming of traditional shRNAs’ 3P arm encoding the 
RNAi trigger. Likely due the saturating transcription rates of U6-driven RNAPIII that 
produce toxicity, high levels of knockdown are observed with and without the addition of a 
mid-stem bulge. We also observe heterogeneity in guide strand positioning, in agreement 
with previous reports, a trait of these traditional shRNAs that seems to be ignored. In vitro 
introduction of uridyl-tailed precursors show other negative details associated with traditional 
shRNA design: inhibition of Dicer processing and accelerated degradation that align with 
DIS3-associated precursor surveillance. This precursor surveillance system provides an 
interesting explanation for our final observation: that the mere expression of these traditional 
shRNA structures perturbs endogenous surveillance activity, inducing increases in 3’ 
oligouridylation and decreases in trimming of endogenous miRNA precursors. These data 
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together contribute to a recommendation to depart from traditional shRNA structures in 
research and clinical use, instead embracing more miRNA-like shRNAs, shRNAs that don’t 
straddle Dicer-independent vs. Dicer-dependent pathways. 
 
Materials and Methods 
 Deep sequencing and luciferase assays were completed as described in Chapter 2, as 
well as in a previous publication from our lab (Newman et al. 2011). 
In vitro transcription time course  
 In vitro transcripts for precursors with the appropriate length uridine tails were 
produced as described previously (Newman et al. 2008). Equivalent amounts of gel-purified, 
internally-radiolabelled precursors were exposed to S100 lysates from N1E, HeLa, or P19 
cell lines, or immuno-precipitated Dicer, as indicated. At the noted time points, equivalent 
fractions of a master mix were spiked into Trizol, precipitated, and run on a denaturing 
polyacrylamide gel, dried, and imaged. Graphs of degradation or Dicer products were 
produced via quantification of bands using ImageJ software. Error bars are the standard 
deviations from independent experiments. 
 In vitro transcripts were produced with annealing of a forward binding primer to the 
full-length oligo. Sequence for T7 forward primer: gactagTAATACGACTCACTATA. WT 
sequences are shown; 3’ uridines were added as labeled for each precursor species. mmu-
miR-103-1: 5’-TAATACGACTCACTATAGGCTTCTTTACAGTGCTGCCTTGTTGCAT 
ATGGATCAAGCAGCATTGTACAGGGCTATGA-3’. Mmu-miR-27b: 5’-TAATACGAC 
TCACTATAAGAGCTTAGCTGATTGGTGAACAGTGATTGGTTTCCGCTTTGTTCAC
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AGTGGCTAAGTTCTGC-3’. Mmu-miR-25: 5’-TAATACGACTCACTATAAGGCGGAG 
ACTTGGGCAATTGCTGGACGCTGCCCTGGGCATTGCACTTGTCTCGGTCTGA-3’. 
Results 
 We studied the same guide/passenger strands as in Chapter 2, but within the pLKO, 
U6-RNAPIII traditional shRNA context, again observing high levels of cleavage and 
trimming, with >99% of precursors’ trigger strands degraded. This is likely Ago-associated, 
not due to the 5U tail, as a similar length sequence lacking secondary structure but 
maintaining the 5U tail was relatively stable in its length (non-templated additions not 
included in this positional analysis) (Fig. 3.1A). We observed high levels of guide strand 
production, but heterogeneity in guide strand positioning, with ~99% of 5’ initial nucleotide 
of guide strand beginning one nucleotide later than expected. Heterogeneity of positioning at 
3’ terminus of guide strand is almost entirely templated but non-targeting 3’ oligo-uridine. 
Together, these changes produce guide strands of ~24 nts in length, as opposed to the 
expected 21. Figure 3.1B presents the combined precursor-specific deep sequencing position 
of 3’ terminus as a percentage of total reads for both Col1A1 and Fox3 shRNAs, combined, 
in comparison to the oligo-uridyl tailed, unstructured transcript (Fig 3.1B). As expected due 
to the high levels of guide strand produced (data not shown), a bulged stem replaced the 
perfectly base-paired stem without changing the high level of reporter activity (Fig. 3.1C).  
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Figure 3.1: High levels of RNAi activity undeterred by heterogeneous processing. (A) 
Both Col1A1 and Fox3 shRNA precursor deep sequencing reads were binned by 3’ terminus 
position as a position of their total reads. Positional percentages were added and then halved 
to present a combined snapshot of positional data for perfectly-stemmed shRNA precursors. 
This was compared to the positional preferences as a percentage of that species’ total for 
unstructured, empty-vector, 5-uridine tailed transcript. (B) Position of 5’ and 3’ terminus of 
intended 3P guide strands for sh-Col1A1 and sh-Fox3, is shown as a fraction of that species’ 
total reads. (C) Single-copy transduced 3T3 cells, transfected with PsiCHECK reporter as in 
Chapter 2, comparing perfectly stemmed Col1A1 and Fox3 reporter activity to single 
nucleotide bulge at position #9 from the 5’ phosphate, normalized to unstructured pLKO-5T 
empty vector. 
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 To isolate the contribution of the uridine tail to degradation and Dicer processing, we 
utilized in vitro transcription of uridine-tailed pre-miR-25 and pre-miR-27b, exposed to S100 
crude cell extracts for 20 minute time courses, revealing decreases in stability inversely 
proportional to the length of the tail (Fig 3.2A). Tails of 3-uridines and longer were 
compared to wild type precursors without untemplated additions, and tails of all sizes 
inhibited the production of mature-sized products. Additionally, these same time courses 
showed reductions in production of mature-sized miRNAs. To isolate whether this inhibition 
of Dicer processing wasn’t due to degradation, we exposed the radiolabeled tailed and 
untailed precursors to immunoprecipitated Dicer, observing a direct inhibition on processing 
by the tail (Fig 3.2B). Of particular note, a 3-uridine tail, added to an endogenous precursor’s 
WT 2 nucleotide overhang, shown to inhibit Dicer processing, produces the total length of 
overhang as encoded by traditional RNAPIII shRNAs. 
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Figure 3.2: Uridyl-tailed precursors induce degradation and inhibit Dicer processing in 
vitro. (A) Radiolabeled, in vitro transcribed pre-miR-27b and -25 with uridine tails of labeled 
lengths were exposed to N1E, HeLa, or P19 crude S100 cell lysates, with the leftmost lane 
for an initial lane time point 0, and subsequent lanes dividing the remaining time evenly. (B) 
Dicer was immunoprecipitated from HeLa lysates to isolate processing from degradatory 
activity. A 60-minute time course gel exposure with pre-miR-27b is shown; the graph 
combines ImageJ quantitation of Dicer product-sized from pre-miR-27b and pre-miR-25. 
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A large fraction of endogenous miRNA precursors terminate in a tri-uridine tail, a 
feature that we have shown to negatively impact stability, and separately, Dicer processing in 
vitro, which aligns with the DIS3 exonuclease preference for >2nt overhangs. In a TUT-4 
knockdown, we observed changes in the tailing profile: total precursors reads that were 
oligouridylated minimally decreased from 5% to 3.5% for the TUT-4 shRNA-expressing 
cells, compared to WT (Fig 3.3A). Regardless, deep sequencing supported our in vitro time 
course observations that oligouridylation decreased stability. The precursors with the most 
dynamic changes in oligouridylation after TUT-4 shRNA expression show an inverse 
correlation with total reads (Fig 3.3A). However, the startling observations came from non-
targeting (scramble and anti-GFP) shRNAs: we observed an increase in overall endogenous 
miRNA precursor oligouridylation vs. WT cells. Upon further analysis, though a higher 
percentage of all endogenous precursors were oligouridylated in shRNA-expressing cells, 
trimming was reduced (Fig 3.3B). Subsequently, we ceased attempting to use shRNAs to 
knockdown RNAi uridylation machinery, and verified via different non-targeting shRNAs, 
perturbation of precursor miRNA surveillance: oligo-uridylation is induced, while 3’-5’ 
degradation of endogenous precursors is inhibited (Fig 3.3C). 
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Figure 3.3: shRNA expression perturbs endogenous precursor miRNAs’ tailing and 
degradation. (A) qPCR-verified knockdown of TUT-4 mRNA in N1E cells stably 
transduced with pLKO sh-TUT4; RNA from which was used to produce a precursor-specific 
deep sequencing library, with the total reads, and percentage of total that are uridylated 
shown. (B) Pre-miRNAs with dynamic changes in oligouridylation after sh-TUT4 expression 
in N1E cells were segregated into two bins: those that increased oligouridylation by more 
than 20% (17 of 219 pre-miRNAs tracked) vs. those that decreased oligouridylation by more 
than 20% (41 of 219). Fold change in fraction oligouridylated is shown for each bin, in 
comparison to fold change in total reads per million, for each bin. (C) Percentage of total 
endogenous pre-miRNA reads for oligo-uridylation, trimming, and tri-uridylation, are shown 
for the N1E cells expressing the labeled shRNA. 
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Discussion 
Using precursor-specific deep sequencing, we report extensive internal cleavage and 
trimming of perfectly stemmed U6/RNAPIII shRNAs, independent of the degradative 5-
uridine tail signal. Furthermore, shRNA expression perturbs endogenous precursor 
uridylation and trimming. These oligouridylated precursors are no longer optimal Dicer 
substrates; and should undergo DIS3 3’-5’ degradation. If they are processed by Dicer and 
are 3P miRNAs, targeting activity will be modified due to the non-templated uridine tail, 
heterogeneity that occurs for 3P traditional shRNAs as well. 
It’s interesting to speculate whether Ago1/3/4 are clogged with precursor shRNA due 
to their difficulty unwinding highly stable duplexes, reducing endogenous miRNA activity. It 
would be very interesting to test total small RNA vs. Ago-associated RNA quantities in the 
presence or absence of traditional shRNAs. Recently, another report of RNAi pathway 
defects due to shRNA expression was released: dysregulated endo-siRNA expression and 
spermatogenic defects; they didn’t observe any changes in miRNA expression levels via 
qPCR (Song et al. 2015). However, as previously published, and as we employed in Chapter 
2, the Ago-associated fraction of small RNAs indicates potential activity, total quantity does 
not; endogenous miRNA activity may be reduced in the presence of shRNA expression, but 
not observed via qPCR (Flores et al. 2014). 
If traditional shRNA design isn’t modified, it’s likely that Ago2 produces the 
unintended miR-451 like guide strands from the 5P + loop instead of the 3P, explaining the 
heterogeneity in the guide strands for the HCV therapeutic as well as the off-target effects 
arising from a different pLKO/TRC clone (Denise et al. 2014; Bhinder et al. 2014b). Off-
target effects produced via non-canonical, Dicer-independent processing, or the 
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heterogeneity of the TT-034 HCV therapeutic, should be reduced via introduction of a mid-
stem bulge that inhibits Ago-like slicing and subsequent trimming of the 3P, with no change 
in efficacy as we report at single-copy. 
We observed high levels of knockdown for traditional shRNAs, leaving little room 
for improvements in increased RNAi activity, even at single-genomic copy contexts. 
However, an H1 promoter that drives RNAPIII is a popular alternative to U6, alleviating 
toxicity through reduced levels of transcription, but also losing efficacy, likely due through 
both decreased levels of transcription and increased heterogeneity in initiating nucleotide 
position of the transcript (Shimizu et al. 2009; Ma et al. 2014a). Alternately, the U6 promoter 
in the HCV therapeutic was modified to attenuate its level of transcription to alleviate 
toxicity (Lavender et al. 2012). Increases in RNAi efficacy observed after blocking 
degradation as in Chapter 2, via incorporation of mid-stem bulges, may still assist traditional 
shRNA efficacy if they’re transcribed from weaker promoters than U6. 
Perturbation of endogenous precursor modifications counterintuitive to the current 
model indicates saturation, perhaps of DIS3. If traditional shRNAs are competing for 
exosome activity, it would be interesting to determine whether substrates outside of RNAi 
are affected (Lee et al. 2014; Kiss and Andrulis 2010). Together, these data suggest that 
traditional shRNAs are a subpar tool with which to dissect the mechanisms and regulation of 
RNAi, and may also have unintended effects on other RNA biology pathways that use 
oligouridylation as a degradative signal/substrate. 
 One of the bullet points that ends up in the pro column when shRNAs are compared 
to shRNAmirs is the perceived accuracy and precision of cleavage positioning. It was 
previously assumed that skipping Drosha processing would allow the most effective, 
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accurate, and precise production of the desired guide strand. The 5U tail and heterogeneity 
observed with small RNA initiation of transcription produce guide strands with large 
variations between actual and expected products. In comparison, increased knowledge 
surrounding substrate preferences that produce accurate and precise Drosha and Dicer 
cleavage products, in addition to our recommended inclusion of mid-stem bulge to inhibit 
Ago-like degradation of the 3P strand, should allow a researcher to obtain much more precise 
and accurate in vitro and in vivo production of desired guide strands (Gu et al. 2012; Ma et al. 
2013).  
A recent paper recommended returning as close to the miR-30 backbone as possible, 
placing the trigger on the 5P strand, re-inserting a 5’ bulge as well as a mid-stem asymmetric 
bulge (Zeng et al. 2013). This should inhibit unintended 3P cleavage that could allow 
incorporation of the loop into the guide strand via miR-451-like biogenesis, and the 
additional 5’ bulge should enhance strand bias for the 5P as well (Schwarz et al. 2003). Now 
that we know more about Dicer and Drosha preferences, increasing the accuracy and 
precision of cleavages from engineered substrates, in combination with the heterogeneity 
arising from Dicer-dependent and –independent pathways presented here and in Chapter 2, 
future harnessing of RNAi should not entail usage of traditional U6/RNAPIII shRNAs. 
Regardless of whether AgoshRNAs or Dicer-only shRNAmirs turn out to be optimal 
for research and/or therapeutic use, it seems unwise to use shRNA substrates that straddle 
both mechanisms. If a traditional shRNA is designed with a 3P trigger, cleavage destroys the 
3P strand. If a traditional shRNA is designed with a 5P trigger, cleavage allows incorporation 
of the loop and potentially some of the 3P strand into RISC, modifying the RNAi activity 
profile.  
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Table 3.1. Chapter 3 summary 
Traditional U6/RNAPIII shRNAs inefficiently harness RNAi 
 Traditional shRNAs are extensively degraded. 
 
 Inclusion of degradation-inhibiting mid-stem bulges doesn’t increase 
RNAi activity from the high level produced by traditional structure. 
 
 shRNA expression dysregulates precursor surveillance: oligouridylation 
of endogenous pre-miRNAs increases and degradation decreases. 
 
 Oligouridyl tail added to endogenous precursors and encoded into 
traditional shRNA 3’ terminus induces clearance and inhibits Dicer 
processing. 
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